Related Experiment Video
Updated: Aug 15, 2026

Studying Protein Function and the Role of Altered Protein Expression by Antibody Interference and Three-dimensional Reconstructions
Published on: April 21, 2016
Phenylketonuria and its variants: observations on intellectual functioning
Insights
Early diagnosis and dietary treatment are crucial for phenylketonuria (PKU) patients. Timely intervention significantly improves intelligence quotient (IQ) outcomes in individuals with classic PKU, preventing cognitive impairment.
Area of Science:
- Metabolic Disorders
- Neurodevelopmental Pediatrics
- Genetics
Background:
- Phenylketonuria (PKU) is an inherited metabolic disorder requiring lifelong management.
- Cognitive outcomes in PKU patients are influenced by diagnosis timing and treatment adherence.
- Long-term observational data on PKU variants and their intellectual development are essential.
Purpose of the Study:
- To investigate the impact of age at diagnosis and dietary treatment on intelligence quotient (IQ) in patients with PKU and its variants.
- To compare intellectual outcomes between patients with classic PKU, atypical PKU, and persistent benign hyperphenylalaninemia.
- To identify critical factors influencing long-term cognitive development in PKU.
Main Methods:
- Longitudinal observation of 119 patients with PKU and its variants.
- Analysis of age at diagnosis, dietary treatment protocols (timely, late, adequate, over-treatment), and resulting IQ scores.
- Comparative analysis of IQ across different PKU subtypes and treatment groups.
Main Results:
- Late diagnosis (>2 months) in classic PKU correlated with a mean IQ of 57.6.
- Early diagnosis and treatment in classic PKU yielded higher mean IQs (93.6 when treated, 99.3 at age 5, 92.7 at age 15).
- Atypical PKU patients treated early showed high mean IQs (110.0), while untreated persistent benign hyperphenylalaninemia patients had a mean IQ of 104.2.
Conclusions:
- Very early diagnosis (by 2 weeks) and immediate dietary therapy initiation are paramount for optimal IQ in classic PKU.
- Dietary management and treatment adherence significantly impact cognitive outcomes across PKU variants.
- Understanding the nuances of treatment (adequate vs. over-treatment) is vital for preventing malnutrition and optimizing development.
Abstract:
The age at diagnosis, dietary treatment and intelligence quotient (IQ) of 119 patients with phenylketonuria (PKU) and its variants who were under long-term observation were studied. In 27 of the 79 patients with classic PKU the diagnosis had been made and treatment begun late (after 2 months of age). The mean IQ of these 27 patients was 57.6 when they were in their early 20s (although 2 had normal IQs). In contrast, among the 52 patients with classic PKU who were not treated late the mean IQ was 93.6 for the 27 who were still receiving dietary therapy. The mean IQs were 99.3 and 92.7 at ages 5 (when the diet was discontinued) and 15 years respectively for the 12 who had been treated "adequately". It was 76.0 for the 13 who were "over-treated" (malnourished) in the first 6 months of life. Among the patients with atypical PKU, who were treated early, the mean IQs were 110.0 for the 7 who were still receiving dietary therapy and 102.7 for the 12 who were not. The 21 patients with persistent benign hyperphenylalaninemia, who were not treated, had a mean IQ of 104.2. The most important factor in the ultimate IQ of patients with classic PKU is very early diagnosis (by 2 weeks of age) along with immediate initiation of dietary therapy.
More Related Videos
08:22A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations
Published on: December 1, 2017
11:01Quantitative Autoradiographic Method for Determination of Regional Rates of Cerebral Protein Synthesis In Vivo
Published on: June 28, 2019
Related Concept Videos
Overview of Protein Metabolism
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Inborn Errors of Metabolism
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Language and Cognition
Intellectual Disability